NCT06813261: GRACE

GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women

Recruiting now NA Last updated 8 September 2025

What this trial tests

NA trial testing GLYLO in Postmenopause in 30 participants. Currently enrolling.

Timeline

1 April 2025

Primary endpoint
30 April 2026

30 June 2026

Quick facts

Lead sponsor	Buck Institute for Research on Aging
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	other
Enrollment	30
Start date	1 April 2025
Primary completion	30 April 2026
Estimated completion	30 June 2026
Sites	1 location across United States

Drugs / interventions tested

• GLYLO
• Placebo

Conditions studied

• Postmenopause — all drugs for Postmenopause →
• Metabolism — all drugs for Metabolism →
• Geroscience — all drugs for Geroscience →

Sponsor

Buck Institute for Research on Aging

Who can join

Adults 45 to 65, female only, with Postmenopause or Metabolism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to assess the effectiveness of GLYLO, a dietary supplement, in postmenopausal women aged 45 to 65 who are overweight or obese and have elevated HbA1c levels. Specifically, the study seeks to evaluate whether GLYLO can reduce advanced glycation end products (AGEs) levels, which are harmful compounds formed when sugar attaches to proteins or fats in the body and can contribute to aging and disease. The primary outcome of the study is to determine if GLYLO reduces AGEs, enhances metabolic and hormonal health, and mitigates age-related functional decline.

This study includes one screening visit and three testing visits over a 6-month period. After eligibility is confirmed, participants will be randomly assigned to one of two groups to take either GLYLO (two capsules daily) or a placebo at home for 24 weeks. Participants will provide blood samples at every visit. During the three testing visits, they will complete physical performance and cognitive function tests, provide both blood and urine samples, and fill out quality of life and 24-hour dietary intake questionnaires. The dietary intake questionnaires will be completed only twice i.e. at the baseline visit and again at the final 6-month visit.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Reduction of glycation stress as a geroscience intervention: protocol for a pilot RCT in postmenopausal women.
   Tanwar V, Kapahi P, Newman JC, Stubbs B. · · 2026 · PMID 42026060 · DOI 10.1038/s41514-026-00373-x